BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bimzelx (bimekizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bimzelx (bimekizumab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06921850-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06921850)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in C
 hildren and Adolescents With Moderate to Severe Hidradenitis Suppurativa\n
 Estimated primary completion: 21 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06921850
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06506916)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarker
 s in Study Participants With Moderate to Severe Plaque Psoriasis\nEstimate
 d primary completion: 9 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06506916
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497620-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Bimzelx (bimekizumab): Phase 4 readout est. (NCT07497620)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 4.\nStudy: Bimzelx (Bimekizumab) 
 For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)\nEstimated
  primary completion: 1 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07497620
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219420-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT07219420)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Bimekizumab in Study Participants With Palmoplant
 ar Pustulosis\nEstimated primary completion: 27 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07219420
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888193-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bimzelx (bimekizumab): Phase 1 readout est. (NCT06888193)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 1\, Psoriatic Arthritis.\nStudy: 
 A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk F
 rom Mothers Receiving Treatment With Bimzelx® (Bimekizumab)\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06888193
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668181-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06668181)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekiz
 umab in Pediatric Study Participants With Active Juvenile Idiopathic Arthr
 itis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankyl
 osing Spondylitis) and Juvenile Psoriatic Arthritis\nEstimated primary com
 pletion: 12 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bimekizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668181
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290036-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280518
DTEND;VALUE=DATE:20280519
SUMMARY:Bimzelx (bimekizumab): Phase 1 readout est. (NCT07290036)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 1\, Psoriatic Arthritis.\nStudy: 
 A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves 
 Similarly Throughout the Body Over Time in Adults\nEstimated primary compl
 etion: 18 May 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 imekizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07290036
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767864-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bimzelx (bimekizumab): Phase 2 readout est. (NCT07767864)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 2.\nStudy: Efficacy of Bimekizuma
 b in Adults With Pyoderma Gangrenosum\nEstimated primary completion: June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bimekizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0776786
 4
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742333-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Bimzelx (bimekizumab): Phase 2 readout est. (NCT06742333)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 2\, Psoriasis.\nStudy: Early Inte
 rvention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflamm
 ation?\nEstimated primary completion: 22 July 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06742333
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06425549-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06425549)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriasis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab i
 n Children and Adolescents From 6 Years to Less Than 18 Years of Age With 
 Moderate to Severe Plaque Psoriasis\nEstimated primary completion: 21 Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bimekizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0642
 5549
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836283-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20300415
DTEND;VALUE=DATE:20300416
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT07836283)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriasis.\nStudy: Evaluation
  of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in th
 e Treatment of Anterior Chest Wall Pain Associated With Active Axial Spond
 yloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimeki
 zumab\nEstimated primary completion: 15 April 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07836283
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-92@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Bimzelx (bimekizumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 4\, Psoriasis.\nStudy: Utilizatio
 n of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary 
 completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bimekizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07352566
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
